@Fistein:$IX Biopharma(42C.SI)$ 0.8 Target Price. --iX Biopharma Ltd(42C) Growth Catalysts-- Shift towards commercialisation of WaferiX subligual delivery of drugs could bump up revenue by as much as 250% in FY-2026, backed by planned capacity expansion. Out-licensing of the sublingual ketamine wafer, Wafermine, for Phase 3 development will be a major catalyst and expected to turn iX Biopharma profitable in long-term. Specialty pharmaceutical and nutraceutical drugs will benefit from the planned six-fold increase in production capacity to meet the expected surge in demand. Investment Merits Out-licensing world's first sublingual ketamine formula, Wafermine, for Phase 3 development is a near-term catalyst. Since the completion of its end-of-Phase 2 meetin

@StayClose:$Tradr 2X Short TSLA Daily ETF(TSLQ)$  $Tesla Motors(TSLA)$   Support / Resistance 📈📉: Support: $374, $364, $357-358 Resistance: $382.5, $393, $403 Outlook 📝: Today, TSLA opened above $377. If TSLA manage to hold $374, we should be able to see more short term upside towards $382.5 If TSLA break and hold $382.5, we maybe able to see $393. If TSLA rejects at $382.5, then watch for $374 support. Else if TSLA rejects at $374, then watch for support back at $364. If TSLA rejects at $364, then watch for support at $357-358. Target 🎯: Entered these TSLQ position when TSLA was trading around $382 level. Should be exiting all positions today, will slowly scale out as TSLA trades back towards $374. T